Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
Scinai Immunotherapeutics (NASDAQ: SCNI) has announced its participation in the BIO-Europe Spring 2025 conference in Milan, Italy, from March 17-19. The company's leadership team, including CEO Amir Reichman, CTO Dr. Dalit Weinstein-Fischer, and Business Development Director Solomon Gahtan, will engage with various stakeholders.
The company will focus on three main objectives: showcasing their inflammation and immunology (I&I) product pipeline to potential pharma partners interested in co-development or licensing of NanoAbs, presenting their end-to-end biologics CDMO services, and meeting with institutional and private investors. Interested parties can schedule meetings through the conference partnering platform or by emailing bd@scinai.com. Scinai will maintain presence at exhibitor booth #22 throughout the conference.
Scinai Immunotherapeutics (NASDAQ: SCNI) ha annunciato la sua partecipazione alla conferenza BIO-Europe Spring 2025 che si terrà a Milano, Italia, dal 17 al 19 marzo. Il team di leadership dell'azienda, incluso il CEO Amir Reichman, il CTO Dr. Dalit Weinstein-Fischer e il Direttore dello Sviluppo Commerciale Solomon Gahtan, interagirà con vari stakeholder.
L'azienda si concentrerà su tre obiettivi principali: presentare il proprio portafoglio di prodotti per l'infiammazione e l'immunologia (I&I) a potenziali partner farmaceutici interessati alla co-sviluppo o alla licenza di NanoAbs, presentare i propri servizi CDMO biologici end-to-end e incontrare investitori istituzionali e privati. Le parti interessate possono pianificare incontri tramite la piattaforma di partnering della conferenza o inviando un'email a bd@scinai.com. Scinai sarà presente allo stand espositivo n. 22 per tutta la durata della conferenza.
Scinai Immunotherapeutics (NASDAQ: SCNI) ha anunciado su participación en la conferencia BIO-Europe Spring 2025 que se llevará a cabo en Milán, Italia, del 17 al 19 de marzo. El equipo directivo de la empresa, incluido el CEO Amir Reichman, el CTO Dr. Dalit Weinstein-Fischer y el Director de Desarrollo Comercial Solomon Gahtan, interactuará con diversos interesados.
La empresa se centrará en tres objetivos principales: mostrar su cartera de productos de inflamación e inmunología (I&I) a posibles socios farmacéuticos interesados en co-desarrollo o licencias de NanoAbs, presentar sus servicios CDMO biológicos de extremo a extremo y reunirse con inversores institucionales y privados. Las partes interesadas pueden programar reuniones a través de la plataforma de colaboración de la conferencia o enviando un correo electrónico a bd@scinai.com. Scinai mantendrá presencia en el stand de exhibición n.º 22 durante toda la conferencia.
Scinai Immunotherapeutics (NASDAQ: SCNI)는 2025년 3월 17일부터 19일까지 이탈리아 밀라노에서 열리는 BIO-Europe Spring 2025 컨퍼런스에 참여한다고 발표했습니다. CEO Amir Reichman, CTO Dr. Dalit Weinstein-Fischer, 비즈니스 개발 이사 Solomon Gahtan을 포함한 회사의 리더십 팀은 다양한 이해관계자와 소통할 예정입니다.
회사는 세 가지 주요 목표에 집중할 것입니다: 염증 및 면역학(I&I) 제품 파이프라인을 공동 개발 또는 NanoAbs 라이센스에 관심이 있는 잠재적 제약 파트너에게 소개하고, 엔드 투 엔드 생물학적 CDMO 서비스를 제공하며, 기관 및 개인 투자자와 만나는 것입니다. 관심 있는 당사자는 컨퍼런스 파트너링 플랫폼을 통해 회의를 예약하거나 bd@scinai.com으로 이메일을 보낼 수 있습니다. Scinai는 컨퍼런스 기간 동안 전시 부스 #22에 상주할 것입니다.
Scinai Immunotherapeutics (NASDAQ: SCNI) a annoncé sa participation à la conférence BIO-Europe Spring 2025 qui se tiendra à Milan, en Italie, du 17 au 19 mars. L'équipe de direction de l'entreprise, y compris le PDG Amir Reichman, le CTO Dr. Dalit Weinstein-Fischer et le Directeur du Développement Commercial Solomon Gahtan, interagira avec divers acteurs concernés.
L'entreprise se concentrera sur trois objectifs principaux : présenter son portefeuille de produits en inflammation et immunologie (I&I) à des partenaires pharmaceutiques potentiels intéressés par le co-développement ou la licence de NanoAbs, présenter ses services CDMO biologiques de bout en bout, et rencontrer des investisseurs institutionnels et privés. Les parties intéressées peuvent planifier des réunions via la plateforme de partenariat de la conférence ou en envoyant un e-mail à bd@scinai.com. Scinai sera présent au stand d'exposition n° 22 tout au long de la conférence.
Scinai Immunotherapeutics (NASDAQ: SCNI) hat seine Teilnahme an der BIO-Europe Spring 2025 Konferenz in Mailand, Italien, vom 17. bis 19. März angekündigt. Das Führungsteam des Unternehmens, einschließlich CEO Amir Reichman, CTO Dr. Dalit Weinstein-Fischer und Direktor für Geschäftsentwicklung Solomon Gahtan, wird mit verschiedenen Interessengruppen in Kontakt treten.
Das Unternehmen wird sich auf drei Hauptziele konzentrieren: die Präsentation ihres Produktportfolios für Entzündung und Immunologie (I&I) potenziellen Pharma-Partnern, die an einer Co-Entwicklung oder Lizenzierung von NanoAbs interessiert sind, die Vorstellung ihrer End-to-End-Biologika-CDMO-Dienste und Treffen mit institutionellen und privaten Investoren. Interessierte Parteien können Meetings über die Partnering-Plattform der Konferenz planen oder eine E-Mail an bd@scinai.com senden. Scinai wird während der gesamten Konferenz am Messestand Nr. 22 präsent sein.
- None.
- None.
Scinai's CEO, Mr. Amir Reichman, CTO, Dr. Dalit Weinstein-Fischer and Business Development Director, Mr. Solomon Gahtan will be holding meetings during the conference days with:
- Potential pharma partners in the field of I&I and dermatology interested in co-developing or in-licensing one of Scinai's innovative NanoAbs.
- Prospective clients of the company's end-to-end biologics CDMO services.
- Institutional and private investors interested in Scinai's value proposition.
Additional interested parties are encouraged to schedule a meeting through the conference partnering platform or to email Scinai at bd@scinai.com to schedule a meeting. Throughout the conference, Scinai will also be available at exhibitor booth #22 to showcase its CDMO services.
About Scinai Bioservices CDMO
In 2024, Scinai launched its CDMO business unit, branded as Scinai Bioservices, operating from the Company's site in
Since its inception, the CDMO unit has executed drug development projects for multiple biotech companies. These activities have included upstream and downstream process development, scale-up, analytical methods development and drug manufacturing for pre-clinical and clinical trials. Additionally, the Company has partnered with Ayana Pharma to provide liposomal encapsulated drug development services.
Scinai's
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique Biologics CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
CDMO and Partnering | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that we won't raise any capital under SEPA or that we will not otherwise benefit from the SEPA as currently anticipated; lower than anticipated revenues of Scinai's CDMO business; the risk that Scinai's expanded presence in the
Photo - https://mma.prnewswire.com/media/2642473/Scinai_Immunotherapeutics_Ltd.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/scinai-to-connect-with-investors-showcase-its-innovative-ii-pipeline-and-its-boutique-cgmp-biologics-cdmo-during-bio-europe-spring-2025-302402918.html
SOURCE Scinai Immunotherapeutics Ltd.